So far, only a few studies evaluated the potential of TDP‐43 as a biomarker using enzyme‐linked immunosorbent assay (ELISA) or western blot analysis in CSF of ALS patients with heterogeneous results.3 This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.